Aurore Laprais

Dr. Aurore Laprais

Ottawa Animal Emergency and Specialty Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
Aurore LapraisAurore Laprais
Aurore Laprais
Thierry OlivryThierry Olivry
Thierry Olivry
CCNU and other treatment protocols are commonly offered to owners for the treatment of dogs diagnosed with cutaneous (epitheliotropic) T-cell lymphoma (CTCL). Chemotherapy protocols provide variable benefits; they have different side-effects, and they typically require monitoring to detect drug toxicity at a non-negligible cost to the owner. At this time, even though CCNU is most often recommended to treat dogs with CTCL, there is no clear consensus on the benefit of this drug. Knowing which chemotherapy protocol yields the highest rate of complete remission and longest survival times would help veterinarians and pet owners select treatment options based on the best evidence available. Our objective was to review the literature to compare the complete remission rates and survival times of CCNU-based protocols to those of other interventions. We critically assessed the data included in articles reporting treatment outcome in at least five dogs with CTCL. Single case reports and case series with less than five patients were not reviewed to avoid anecdotal evidence of lower quality. The search for, and review and analysis of, the best evidence available as of February 8, 2017, suggests that CCNU and pegylated liposomal doxorubicin appear to yield the highest rate of complete remission in approximately one-third of dogs with CTCL. Other treatment protocols did not report usable information on remission rates. Without any treatment, the mean/median survival time in dogs with CTCL varied between 3 and 5 months. With CCNU protocols, the median survival time was 6 months and the one with retinoids (isotretinoin and/or etretinate), PEG L-asparaginase or prednisolone monotherapy was 11, 9 and 4 months, respectively; all these durations were obtained from small numbers of dogs, however. CCNU leads to a complete remission of signs in approximately one-third of dogs with CTCL, but such remissions are of short duration. The median survival time after CCNU appears longer than that without treatment, but other drugs appear to provide a better long-term prognosis. Further studies are required to investigate the effect of CCNU, alone or in combination, on remission rates, survival times and impact on quality of life.

30 May 2016 in Veterinary Dermatology
Verified
Journal Article
Closed access
PDF file
CTChie Tamamoto‐Mochizuki
Chie Tamamoto‐Mochizuki
FBFrane Banovic
Frane Banovic
PBPetra Bizikova
Petra Bizikova
Aurore LapraisAurore Laprais
Aurore Laprais
KLKeith E. Linder
Keith E. Linder
Thierry OlivryThierry Olivry
Thierry Olivry

7 September 2020 in Genes
Verified
Journal Article
Open access
PDF file
SKSarah Kiener
Sarah Kiener
Aurore LapraisAurore Laprais
Aurore Laprais
EMElizabeth A. Mauldin
Elizabeth A. Mauldin
VJVidhya Jagannathan
Vidhya Jagannathan
Thierry OlivryThierry Olivry
Thierry Olivry
Tosso LeebTosso Leeb
Tosso Leeb
In a highly inbred Australian Shepherd litter, three of the five puppies developed widespread ulcers of the skin, footpads, and oral mucosa within the first weeks of life. Histopathological examinations demonstrated clefting of the epidermis from the underlying dermis within or just below the basement membrane, which led to a tentative diagnosis of junctional epidermolysis bullosa (JEB) with autosomal recessive inheritance. Endoscopy in one affected dog also demonstrated separation between the epithelium and underlying tissue in the gastrointestinal tract. As a result of the severity of the clinical signs, all three dogs had to be euthanized. We sequenced the genome of one affected puppy and compared the data to 73 control genomes. A search for private variants in 37 known candidate genes for skin fragility phenotypes revealed a single protein-changing variant, LAMB3:c.1174T>C, or p.Cys392Arg. The variant was predicted to change a conserved cysteine in the laminin β3 subunit of the heterotrimeric laminin-322, which mediates the binding of the epidermal basement membrane to the underlying dermis. Loss-of-function variants in the human LAMB3 gene lead to recessive forms of JEB. We confirmed the expected co-segregation of the genotypes in the Australian Shepherd family. The mutant allele was homozygous in two genotyped cases and heterozygous in three non-affected close relatives. It was not found in 242 other controls from the Australian Shepherd breed, nor in more than 600 other controls. These data suggest that LAMB3:c.1174T>C represents the causative variant. To the best of our knowledge, this study represents the first report of a LAMB3-related JEB in domestic animals.

29 January 2017 in Veterinary Dermatology
Verified
Journal Article
Closed access
PDF file
Aurore LapraisAurore Laprais
Aurore Laprais
SDStanley M. Dunston
Stanley M. Dunston
STSheila M. F. Torres
Sheila M. F. Torres
CFClaude Favrot
Claude Favrot
Thierry OlivryThierry Olivry
Thierry Olivry

28 January 2020 in Current Dermatology Reports
Verified
Journal Article
Closed access
PDF file
PPPascal Prelaud
Pascal Prelaud
Aurore LapraisAurore Laprais
Aurore Laprais

24 April 2017 in Veterinary Dermatology
Verified
Journal Article
Closed access
PDF file
Aurore LapraisAurore Laprais
Aurore Laprais
PBPetra Bizikova
Petra Bizikova
ELErin Lashnits
Erin Lashnits
ATAlison Tucker
Alison Tucker
KLKeith Linder
Keith Linder